iwNHL 2022 Session I: Advances in the treatment of T-cell lymphoma episode artwork

EPISODE · Oct 26, 2022 · 17 MIN

iwNHL 2022 Session I: Advances in the treatment of T-cell lymphoma

from VJHemOnc Podcast · host VJHemOnc

The 19th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2022 took place in Barcelona, Spain, and brought together leading experts in the field as they discussed several topics. In this podcast series, you will hear the latest updates in NHL and gain an insight into the sessions that took place at this year's meeting. The first session from iwNHL focused on advances in the treatment and management of T-cell lymphoma. In this podcast, Laurence de Leval, MD, PhD, Lausanne University Hospital, Lausanne, Switzerland, Steven Horwitz, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY, François Lemonnier, MD, Henri Mondor University Hospital, Créteil, France, and David Sibon, MD, PhD, Henri Mondor University Hospital, Créteil, France, discuss the safety and efficacy of brentuximab vedotin in enteropathy-associated T-cell lymphomas (EATL), epigenetic drugs and TRBC1-directed CAR-T therapy in T-cell lymphoma, and novel developments in the field of cutaneous T-cell lymphoma (CTCL). 

Episode metadata supplied by the publisher feed · Published Oct 26, 2022

Embed this episode

NOW PLAYING

iwNHL 2022 Session I: Advances in the treatment of T-cell lymphoma

0:00 17:40

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of VJHemOnc Podcast?

This episode is 17 minutes long.

When was this VJHemOnc Podcast episode published?

This episode was published on October 26, 2022.

Can I download this VJHemOnc Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!